Japanese company profile · 4582
SymBio Pharmaceuticals Limited
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: シンバイオ製薬株式会社
Name follows the English name recorded in EDINET filer data. English company name source
FY2025 · fiscal year ended December 2025Latest filing date: 2026-03-24What does this company do?
What does this company do?
In its FY2025 public filing, SymBio Pharmaceuticals Limited reports Research, Development, Manufacturing and Sales of Pharmaceutical Products and Related Services. The page shows business-level revenue and profit where the source disclosures support comparison.
SymBio Pharmaceuticals Limited's largest reported business by revenue in FY2025 was Research, Development, Manufacturing and Sales of Pharmaceutical Products and Related Services.
FY2025 · fiscal year ended December 2025 · View original filing ↗ The source document may be in Japanese.
Reported company-wide figures
- Company revenue
- ¥1.31B ↗ FY2025 · fiscal year ended December 2025
- Operating profit
- −¥4.44B ↗ FY2025 · fiscal year ended December 2025
- Comparable margin
- -339.6% ↗ FY2025 · fiscal year ended December 2025
JGAAP · Consolidated company-wide
Company profile
Identity
- Securities code
- 4582
- EDINET code
- E24682
- Corporate number
- 1010401057034
- Listing status
- Listed
- Industry (EDINET filer classification)
- Pharmaceuticals
Location and fiscal year
- Headquarters
- 東京都港区 · As filed in Japanese
- Latest fiscal year
- FY2025
- Accounting standard
- JGAAP
- P16 data snapshot
- 2026-11-07
Company size
- Employees (consolidated)
- 91 people (FY2025)
- Employees (non-consolidated)
- 86 people (FY2025)
- Capital stock
- JPY 19.2 billion (FY2025)
Official information
- Latest annual securities report
- Latest annual securities report Opens in a new tab
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
How does it make money?
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Research, Development, Manufacturing and Sales of Pharmaceutical Products and Related Services | ¥1.31B ↗ | — | −¥4.44B ↗ | -339.6% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Company-wide trend
Company revenue
JGAAP · Consolidated- FY2022
100.0 ¥10.01B - FY2023
55.9 ¥5.59B - FY2024
24.5 ¥2.45B - FY2025
13.1 ¥1.31B
Company revenue
JGAAP · Parent-only- FY2021
100.0 ¥8.26B
Company operating profit
JGAAP · Consolidated- FY2022
44.2 ¥1.96B - FY2023
18.3 −¥811.67M - FY2024
87.3 −¥3.88B - FY2025
100.0 −¥4.44B
Company operating profit
JGAAP · Parent-only- FY2021
100.0 ¥1.02B
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research, Development, Manufacturing and Sales of Pharmaceutical Products and Related Services | ¥10.01B | ¥5.59B | ¥2.45B | ¥1.31B |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
Company profile
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
- Growth—No comparable data
- ProfitabilityPosition among all companies with available values in the fixed reference data.FY2025
0 - Business concentration—No comparable data
- Business change—No comparable data
- Cash generation—No comparable data
- Growth persistencePeer-position scoreFY2022→FY2023, FY2023→FY2024, FY2024→FY2025
1
Source
Public filing
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XNE5
View original filing ↗